Cited by 475Schizophrenia research and treatmentAttention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence

Aman, Michael G., De Smedt, Goedele, Derivan, Albert, Lyons, Ben, Findling, Robert L., Risperidone Disruptive Behavior Study Group·2002·American Journal of Psychiatry

DOI 10.1176/appi.ajp.159.8.1337

Open this paper in CoChat — free account

Abstract

OBJECTIVE: The short-term efficacy and safety of risperidone in the treatment of disruptive behaviors was examined in a well-characterized cohort of children with subaverage intelligence. METHOD: In this 6-week, multicenter, double-blind, parallel-group study of 118 children (aged 5-12 years) with severely disruptive behaviors and subaverage intelligence (IQ between 36 and 84, inclusive), the subjects received 0.02-0.06 mg/kg per day of risperidone oral solution or placebo. The a priori primary efficacy measure was the change in score from baseline to endpoint on the conduct problem subscale of the Nisonger Child Behavior Rating Form. RESULTS: The risperidone group showed significantly greater improvement than did the placebo group on the conduct problem subscale of the Nisonger Child Behavior Rating Form from week 1 through endpoint (change in score of -15.2 and -6.2, respectively). Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score. The most common adverse effects reported during risperidone treatment were headache and somnolence. The extrapyramidal symptom profile of risperidone was comparable to that of placebo. Mean weight increases of 2.2 kg. and 0.9 kg occurred in the risperidone and placebo groups, respectively. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of severely disruptive behaviors in children with subaverage IQ.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.159.8.1337

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Categorical Data Analysis
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Untitled work
(1985) · PubMed · Cited by 1,427
Self-citation
Manual for the Wechsler intelligence scale for children
Wechsler, D. (1974) · Psychological Corp. eBooks · Cited by 1,303
Effective psychosocial treatments of conduct-disordered children and adolescents: 29 years, 82 studies, and 5,272 kids
Brestan, E. V., & Eyberg, S. M. (1998) · Journal of Clinical Child Psychology · doi:10.1207/s15374424jccp2702_5 · Cited by 1,025
The Behavior Problems Inventory: An Instrument for the Assessment of Self-Injury, Stereotyped Behavior, and Aggression/Destruction in Individuals with Developmental Disabilities
Rojahn, J., Matson, J. L., Lott, D., Esbensen, A. J., & Smalls, Y. (2001) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1013299028321 · Cited by 524
Atypical antipsychotics and weightgain — a systematic review
Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 435
The Nisonger CBRF: A child behavior rating form for children with developmental disabilities
Aman, M. G. (1996) · Research in Developmental Disabilities · doi:10.1016/0891-4222(95)00039-9 · Cited by 357
Self-citation
A Double-Blind Pilot Study of Risperidone in the Treatment of Conduct Disorder
FINDLING, R. L., McNAMARA, N. K., BRANICKY, L. A., SCHLUCHTER, M. D., LEMON, E., & BLUMER, J. L. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200004000-00021 · Cited by 309
Self-citation
Aberrant Behavior Checklist
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985) · PsycTESTS Dataset · doi:10.1037/t10453-000 · Cited by 283
Self-citation
Risperidone Treatment for Juvenile Bipolar Disorder: A Retrospective Chart Review
Frazier, J. A., Meyer, M. C., Biederman, J., Wozniak, J. R., Wilens, T. E., Spencer, T. J., KIM, G. S., & SHAPIRO, S. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199908000-00011 · Cited by 236

Show all 49 references

Research works printed but not linked: 1

Chouinard G, Ross-Chouinard A, Annable L, Jones B: Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233

Sorted by citations

Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Evidence-Based Psychosocial Treatments for Children and Adolescents With Disruptive Behavior
Eyberg, S. M., Nelson, M. M., & Boggs, S. R. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701820117 · Cited by 1,335
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
European clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 590
Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology
McDougle, C. J., Scahill, L. D., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., Arnold, L. E., Posey, D. J., Martin, A., GHUMAN, J. K., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1142 · Cited by 477
Self-citation
The Status of Irritability in Psychiatry: A Conceptual and Quantitative Review
Vidal‐Ribas, P., Brotman, M. A., Valdivieso, I., Leibenluft, E., & Stringaris, A. K. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.04.014 · Cited by 493
Four-Year Prospective Outcome and Natural History of Mania in ChildrenWith a Prepubertal and Early Adolescent Bipolar Disorder Phenotype
Geller, B., Tillman, R., Craney, J. L., & Bolhofner, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.5.459 · Cited by 472
The Texas Children's Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder
PLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
Correll, C. U., & Carlson, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 406
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
Hert, M. A. F. D., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 365
National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics
Olfson, M., Blanco, C., Liu, S.-M., Wang, S., & Correll, C. U. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.647 · Cited by 355
Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335
Self-citation
International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions
Kutcher, S., Aman, M. G., Brooks, S. J., Buitelaar, J. K., van Daalen, E., Fegert, J. M., Findling, R. L., Fisman, S., Greenhill, L. L., Huß, M., et al. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00045-2 · Cited by 326
Self-citation
A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial
Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B., & Lieberman, J. A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 310
Contemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L., Erenberg, G., Berlin, C. M., Budman, C., Coffey, B. J., Jankovic, J., Kiessling, L., King, R. A., Kurlan, R., Lang, A., et al. (2006) · NeuroRX · doi:10.1016/j.nurx.2006.01.009 · Cited by 300
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
Nutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Maayan, L. A., & Correll, C. U. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0015 · Cited by 257
Treatment of Young People With Antipsychotic Medications in the United States
Olfson, M., King, M. D., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0500 · Cited by 252
Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines
Gleason, M. M., EGGER, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F., Luby, J. L., Owens, J. A., Scahill, L. D., Scheeringa, M. S., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181570d9e · Cited by 247
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study
Haas, M., DelBello, M. P., Pandina, G., Kushner, S. F., Hove, I. V., Augustyns, I., Quiroz, J. A., & Kusumakar, V. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00750.x · Cited by 227
Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns
Vitiello, B., Correll, C. U., van Zwieten‐Boot, B., Zuddas, A., Parellada, M., & Arango, C. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.008 · Cited by 225
Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview
Matson, J. L., & Neal, D. (2008) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2008.08.007 · Cited by 219
Risperidone Effects in the Presence/Absence of Psychostimulant Medicine in Children with ADHD, Other Disruptive Behavior Disorders, and Subaverage IQ
Aman, M. G., Binder, C. E., & Turgay, A. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041649020 · Cited by 204
Self-citation
Neuropsychopharmacology
Rendleman, R. L., & Walkup, J. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 197
Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents
Cohen, D., Bonnot, O., Bodeau, N., Consoli, A., & Laurent‐Levinson, C. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182549259 · Cited by 194
Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth
Pringsheim, T. M., Panagiotopoulos, C., Davidson, J., Ho, J., & The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group (2011) · Paediatrics & Child Health · doi:10.1093/pch/16.9.581 · Cited by 193
Open-Label, 8-Week Trial of Olanzapine and Risperidone for the Treatment of Bipolar Disorder in Preschool-Age Children
Biederman, J., Mick, E. O., Hammerness, P. G., Harpold, T., Aleardi, M., Dougherty, M., & Wozniak, J. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.019 · Cited by 189
Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents
Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 187
Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents
Patel, N. C., Crismon, M. L., Hoagwood, K., Johnsrud, M. T., Rascati, K. L., Wilson, J. P., & Jensen, P. S. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157543.74509.c8 · Cited by 183
ADouble-Blind, Placebo-Controlled Study of Valproate for Aggression in Youth with Pervasive Developmental Disorders
Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S., Zarcone, J. R., Reese, R. M., Hall, S., Ermer, D. J., Tsai, L. Y., Schroeder, S. R., et al. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.682 · Cited by 187
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder
Bartzokis, G., Lu, P. H., Turner, J., Mintz, J., & Saunders, C. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.039 · Cited by 182
Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment
Sansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A. A., Kaufmann, W. E., Berry‐Kravis, E., Lachiewicz, A. M., Brown, E. C., & Hessl, D. R. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1370-2 · Cited by 182
Atypical antipsychotics for disruptive behaviour disorders in children and youths
Loy, J. H., Merry, S., Hetrick, S. E., & Stasiak, K. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008559.pub3 · Cited by 181
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson, G. M., Scahill, L. D., McCracken, J. T., McDougle, C. J., Aman, M. G., Tierney, E., Arnold, L. E., Martin, A., Katsovich, L., Posey, D. J., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.032 · Cited by 176
Self-citation
Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder
Lecavalier, L., Wood, J. J., Halladay, A. K., Jones, N. E., Aman, M. G., Cook, E. H., Handen, B. L., King, B. H., Pearson, D. A., Hallett, V., et al. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1974-9 · Cited by 184
Self-citation
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L. D., Davies, M., McCracken, J. T., Tierney, E., Nash, P. L., Posey, D. J., et al. (2005) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2005.15.869 · Cited by 170
Self-citation
Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ
Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & The Risperidone Disruptive Behavior Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.677 · Cited by 161
Self-citation
A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment in Children and Adolescents With Disruptive Behavior Disorders
Reyes, M., Buitelaar, J. K., Toren, P., Augustyns, I., & Eerdekens, M. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.402 · Cited by 157
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
Adjunctive Divalproex Versus Placebo for Children With ADHD and Aggression Refractory to Stimulant Monotherapy
Blader, J. C., Schooler, N. R., Jensen, P. S., Pliszka, S. R., & Kafantaris, V. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020233 · Cited by 149
Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis
Almandil, N. B., Liu, Y., Murray, M. L., Besag, F., Aitchison, K. J., & Wong, I. C. K. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0016-6 · Cited by 146
A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia
Haas, M., Unis, A. S., Armenteros, J. L., Copenhaver, M. D., Quiroz, J. A., & Kushner, S. F. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0144 · Cited by 145
A Comparison of Risperidone-Induced Weight Gain Across the Age Span
Safer, D. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000130558.86125.5b · Cited by 144
What Does Risperidone Add to Parent Training and Stimulant for Severe Aggression in Child Attention-Deficit/Hyperactivity Disorder?
Aman, M. G., Bukstein, O. G., Gadow, K. D., Arnold, L. E., Molina, B. S. G., McNamara, N., Rundberg-Rivera, E. V., Li, X., Kipp, H., Schneider, J., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.09.022 · Cited by 143
Self-citation
Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment
Litwin, T., Dušek, P., Szafrański, T., Dzieżyc, K., Członkowska, A., & RYBAKOWSKI, J. K. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318759461 · Cited by 137
Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children
Pringsheim, T. M., Lam, D., Ching, H., & Patten, S. B. (2011) · Drug Safety · doi:10.2165/11592020-000000000-00000 · Cited by 135
Risperidone in Children With Disruptive Behavior Disorders and Subaverage Intelligence: A 1-Year, Open-Label Study of 504 Patients
Croonenberghs, J., Fegert, J. M., Findling, R. L., Smedt, G. D., & Dongen, S. V. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000145805.24274.09 · Cited by 135
Self-citation
Evidence-Based Treatments in Child and Adolescent Psychiatry: An Inventory
McClellan, J., & WERRY, J. S. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00005 · Cited by 137
Prevalence of Psychotropic Drug Use in Adults with Intellectual Disability: Positive and Negative Findings from a Large Scale Study
Tsiouris, J. A., Kim, S.-Y., Brown, W. T., Pettinger, J., & Cohen, I. L. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1617-6 · Cited by 133
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., & Gobbi, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f8770 · Cited by 132
Pharmacotherapy of aggression in children and adolescents: efficacy and effect size.
Pappadopulos, E. A., Woolston, S., Chait, A., Perkins, M. B., Connor, D. F., & Jensen, P. S. (2006) · PubMed Central · Cited by 132
Assessing and treating aggression in children and adolescents with developmental disabilities: a 20‐year overview
Matson, J. L., Dixon, D. R., & Matson, M. L. (2004) · Educational Psychology · doi:10.1080/0144341042000301148 · Cited by 129
Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies
Zuddas, A., Zanni, R., & Usala, T. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.001 · Cited by 121
The Pharmacological Management of Oppositional Behaviour, Conduct Problems, and Aggression in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, and Conduct Disorder: A Systematic Review and Meta-Analysis. Part 2: Antipsychotics and Traditional Mood Stabilizers
Pringsheim, T. M., Hirsch, L., Gardner, D. M., & Gorman, D. A. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000203 · Cited by 120
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 121
Use of antipsychotics in children and adolescents.
Findling, R. L., Steiner, H., & Weller, E. B. (2005) · PubMed · Cited by 118
Self-citation
Effects of Extended Release Methylphenidate Treatment on Ratings of Attention-Deficit/Hyperactivity Disorder (ADHD) and Associated Behavior in Children with Autism Spectrum Disorders and ADHD Symptoms
Pearson, D. A., Santos, C. W., Aman, M. G., Arnold, L. E., Casat, C. D., Mansour, R., Lane, D. M., Loveland, K. A., Bukstein, O. G., Jerger, S. W., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0096 · Cited by 120
Self-citation
Aripiprazole in Children and Adolescents with Tourette Disorder with and without Explosive Outbursts
Budman, C. L., Coffey, B. J., Shechter, R., Schrock, M. D., Wieland, N., Spirgel, A., & Simon, E. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.061 · Cited by 114
Weight Gain Associated with Atypical Antipsychotic Use in Children and Adolescents
Stigler, K. A., Potenza, M. N., Posey, D. J., & McDougle, C. J. (2004) · Pediatric Drugs · doi:10.2165/00148581-200406010-00003 · Cited by 112
Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review
Seida, J. C., Schouten, J. R., Boylan, K., Newton, A. S., Mousavi, S. S., Beaith, A., Vandermeer, B., Dryden, D. M., & CARREY, N. J. (2012) · PEDIATRICS · doi:10.1542/peds.2011-2158 · Cited by 111
Development of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP)
Farmer, C., & Aman, M. G. (2009) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2009.03.001 · Cited by 110
Self-citation
Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents
Calarge, C. A., Ación, L., Kuperman, S., Tansey, M., & Schlechte, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.007 · Cited by 110
Risperidone Augmentation for Treatment-Resistant Aggression in Attention-Deficit/Hyperactivity Disorder
Armenteros, J. L., Lewis, J. E., & Davalos, M. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180323354 · Cited by 110
Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects
Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0120 · Cited by 108
Management of psychiatric disorders in children and adolescents with atypical antipsychotics
Jensen, P. S., Buitelaar, J. K., Pandina, G., Binder, C. E., & Haas, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0580-1 · Cited by 105
Psychopharmacologic Strategies for the Treatment of Aggression in Juveniles
Steiner, H., Saxena, K., & Chang, K. (2003) · CNS Spectrums · doi:10.1017/s1092852900018514 · Cited by 103
A meta-analysis of intervention effects on challenging behaviour among persons with intellectual disabilities
Heyvaert, M., Maes, B., & Onghena, P. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01291.x · Cited by 102
Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study
Haas, M., Eerdekens, M., Kushner, S. F., Singer, J., Augustyns, I., Quiroz, J. A., Pandina, G., & Kusumakar, V. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046177 · Cited by 103
The use of risperidone among individuals with mental retardation: clinically supported or not?
Singh, A. N. A., Matson, J. L., Cooper, C. L., Dixon, D. R., & Sturmey, P. (2004) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2004.07.001 · Cited by 98
Comparison of Risperidone and Methylphenidate for Reducing ADHD Symptoms in Children and Adolescents With Moderate Mental Retardation
Filho, A. G. C., Bodanese, R., da Silva, T. L., Alvares, J. P., Aman, M. G., & Rohde, L. A. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000166986.30592.67 · Cited by 97
Self-citation
Controlled, Blindly Rated, Direct-Interview Family Study of a Prepubertal and Early-Adolescent Bipolar I Disorder Phenotype
Geller, B., Tillman, R., Bolhofner, K., Zimerman, B., Strauss, N. A., & Kaufmann, P. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1130 · Cited by 95
AOne-Year Open-Label Trial of Risperidone Augmentation in Lithium Nonresponder Youth with Preschool-Onset Bipolar Disorder
Pavuluri, M. N., Henry, D. B., Carbray, J. A., Sampson, G., Naylor, M. W., & Janicak, P. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.336 · Cited by 95
Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, or Conduct Disorder
Gorman, D. A., Gardner, D. M., Murphy, A. L., Feldman, M., Bélanger, S. A., Steele, M. M., Boylan, K., Cochrane-Brink, K., Goldade, R., Soper, P. R., et al. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000204 · Cited by 99
Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature
Deb, S. S., & Unwin, G. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282ab9952 · Cited by 92
Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis
McQuire, C., Hassiotis, A., Harrison, B. A., & Pilling, S. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0688-2 · Cited by 91
A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation
Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming, K., & Schroeder, S. R. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0078-1 · Cited by 89
Learning disability
Gillberg, C., & Söderström, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14275-4 · Cited by 88
Practitioner Review: Psychopharmacology in children and adolescents with mental retardation
Handen, B. L., & Gilchrist, R. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01588.x · Cited by 87
Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder
Connor, D. F., McLaughlin, T., & Jeffers-Terry, M. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0007 · Cited by 87
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents
Calarge, C. A., Ellingrod, V. L., Ación, L., Miller, D. D., Moline, J., Tansey, M., & Schlechte, J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328329a60f · Cited by 86
Comorbidity in Pediatric Bipolar Disorder
Joshi, G., & Wilens, T. E. (2009) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.12.005 · Cited by 86
Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study
Consoli, A., Cohen, J. P., Bodeau, N., Guinchat, V., Wachtel, L. E., & Cohen, D. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0320-7 · Cited by 85
Multidisciplinary Assessment and Treatment of Self-Injurious Behavior in Autism Spectrum Disorder and Intellectual Disability: Integration of Psychological and Biological Theory and Approach
Minshawi, N. F., Hurwitz, S., Morriss, D. H., & McDougle, C. J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2307-3 · Cited by 85
The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005–2009
Pringsheim, T. M., Lam, D., & Patten, S. B. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0145 · Cited by 84
A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics
Lee, E. S., Vidal, C., & Findling, R. L. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0037 · Cited by 82
Self-citation
Risperidone and the 5‐ HT2A Receptor Antagonist M 100907 Improve Probabilistic Reversal Learning in BTBR T + tf / J Mice
Amodeo, D. A., Jones, J. H., Sweeney, J. A., & Ragozzino, M. E. (2014) · Autism Research · doi:10.1002/aur.1395 · Cited by 79
Mental Health Care for Children and Adolescents in Foster Care: Review of Research Literature
Landsverk, J. A., Burns, B. J., Stambaugh, L. F., & Rolls-Reutz, J. (2006) · Cited by 79
Aggression in children with attention-deficit/hyperactivity disorder
King, S., & Waschbusch, D. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.146 · Cited by 85
Dopaminergic system genes in childhood aggression: Possible role for DRD2
Zai, C. C., Ehtesham, S., Choi, E., Nowrouzi, B., de Luca, V., Stankovich, L., Davidge, K., Freeman, N., King, N., Kennedy, J. L., et al. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.543431 · Cited by 78
Risperidone Added to Parent Training and Stimulant Medication: Effects on Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, and Peer Aggression
Gadow, K. D., Arnold, L. E., Molina, B. S. G., Findling, R. L., Bukstein, O. G., Brown, N. V., McNamara, N., Rundberg-Rivera, E. V., Li, X., Kipp, H., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.05.008 · Cited by 78
Self-citation
Pharmacotherapy for mental health problems in people with intellectual disability
Ji, N. Y., & Findling, R. L. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000233 · Cited by 80
Self-citation
Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials
Jensen, K. G., Juul, K., Fink‐Jensen, A., Correll, C. U., & Pagsberg, A. K. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.10.002 · Cited by 78
The effect of antidepressants and antipsychotics on weight gain in children and adolescents
Reekie, J., Hosking, S. P. M., Prakash, C., Kao, K., Juonala, M., & Sabin, M. A. (2015) · Obesity Reviews · doi:10.1111/obr.12284 · Cited by 75
Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs
Scheifes, A., Walraven, S., Stolker, J. J., Nijman, H. L. I., Egberts, T. C. G., & Heerdink, E. R. (2015) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2015.11.017 · Cited by 74
Behaviour disorders in children with an intellectual disability
Bélanger, S. A., Brunet, S., D’Anjou, G., Tellier, G., Boivin, J., & Gauthier, M. (2012) · Paediatrics & Child Health · doi:10.1093/pch/17.2.84 · Cited by 73
Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents
Ipser, J., & Stein, D. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0537-6 · Cited by 74
Atypical antipsychotics for disruptive behaviour disorders in children and youths
Loy, J. H., Merry, S., Hetrick, S. E., & Stasiak, K. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008559.pub2 · Cited by 90
Effectiveness, Safety, and Pharmacokinetics of Quetiapine in Aggressive Children With Conduct Disorder
Findling, R. L., Reed, M. D., O’Riordan, M. A., Demeter, C., Stansbrey, R. J., & McNamara, N. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000219832.23849.31 · Cited by 71
Self-citation

Authors: Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group
Affiliations: The Ohio State University (US)
ORCID: Findling, Robert L.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2002-08-01
Volume: 159
Issue: 8
Pages: 1337-1346
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.159.8.1337
OpenAlex: W2133752375
Cited by: 475
References: 49
Citations by year: 2026: 4 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 16 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 13 · 2016: 12 · 2015: 17 · 2014: 17 · 2013: 26 · 2012: 20
FWCI: 18.17
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords: risperidone, disruptive behavior, children with intellectual disabilities, antipsychotic drugs, conduct problems, Aberrant Behavior Checklist, extrapyramidal symptoms, weight gain, adverse effects, hyperactivity, aggression
MeSH terms: Aggression, Child, Double-Blind Method, Female, Humans, Male, Intellectual Disability, Personality Assessment, Placebos, Antipsychotic Agents, Comorbidity, Treatment Outcome, Risperidone, Conduct Disorder, Attention Deficit and Disruptive Behavior Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks